Abusing pharmaceutical opioids has been noticeably rising in human societies in recent years. In spite of the fact that public awareness has raised in this regard, this problem has expanded considerably in many countries. It is self-evident that addiction to pharmaceutical opioids influences societies in diverse economic, social, and cultural perspectives (
1). A study in the USA showed that, from 1996 to 2011, misusing pharmaceutical opioids escalated; this research, however, indicated that the use of illicit drugs decreased in the same period (
2). Researchers generally pay attention to the use of illicit drugs such as heroin and cocaine
, but pharmaceutical opioids are usually ignored (
3).
It is crystal clear that the growing use of pharmaceutical opioids by patients leads to increasing misuse, abuse, and diversion (
4). Although pharmaceutical opioids are beneficial to relieving pain in malignancies such as cancers (
5), during the last years, they have also been increasingly popular in relieving chronic non-cancer pain (
6). For example, using pharmaceutical opioids may be rather a good idea for comforting patients.
However, it can cause some difficulties for them later (
7). Using long-acting opioids in particular can increase their dependency and addiction, ending up in death.
According to reports, 2.1% of the population in the USA abused pharmaceutical opioids in 2009.Moreover, the mortality rate due to using opioids became threefold from 1999 to 2006 (
8). In 2007, the Food and Drug Administration (FDA) implemented a strategy called “the risk evaluation and mitigation strategy” (REMS) (
9),which is applied for the medicines that are effective but have serious risks. According to REMS, producers of these medicines should inform physicians of some information such as proper prescription and attention to opioids users’ misuse and dependency (
10). Unfortunately, there is no experiment indicating that REMS is useful in reducing the use and abuse of pharmaceutical opioids (
11).
Policy-makers’ efforts to reduce and manage the overuse and misuse of pharmaceutical opioids have been unsuccessful (
11). Therefore, tools and interventions are required to address these problems and assist policy-makers in recognizing and solving them properly.
This paper aims to develop a tool named system dynamics as the integrating factors affecting the misuse of pharmaceutical opioids. System dynamics is a way to help researchers to realize the structure of the system and forecast the misleading results (
12).
System Dynamics Model
A system is defined as a set of components working in a regular series. The variables of a linear approach in a system are connected linearly and in one way; however, in the systemic approach, the relations among these variables are not one-sided, but based on cause and effect (
13). Unlike the linear approach, a complex system is a system whose behavior cannot be easily predicted. As we know, people tend to solve problems quickly. They consider their problems as a linear system and do not pay attention to delays in performance results (
14). Hence, they cannot notice the interaction between the subjects, so they make mistakes in solving problems.
Due to the complexity and disturbance in the real world, decision-makers have problems in deciding and solving challenges. Thus, using a simulation system to overcome these disabilities is socially important.
System dynamics is a powerful tool to analyze and simulate cases. It was first developed by Forrester in the 1950s at MIT, but was gradually applied in other fields such as industry, economics, biology, and medical sciences (
12). In some studies, system dynamics is employed in health care systems, including lymphocyte interactions (
15), diagnose in diabetes population (
16), pharmaceutical opioids overdose in chronic pain (
17), and developing programs in healthcare (
18).
Several structures for processing system dynamics have been defined. Generally, SD
consists of four stages, including conceptualization, formulation, testing, and implementation (
19). The first stage is the qualitative phase of SD, and the others are related to quantitative phase (
20).
The qualitative phase defines problems and generates causal loop diagrams (CLD) (
20). The relationship between the factors in a system is not visible; therefore, CLD is applied to demonstrate how a variable affects others (
21). In CLD models, the relationship between variables is demonstrated by arrows (causal link). In the link between two variables, if the increase in a former variable leads to the increase in the latter, this link is named positive. Likewise, if the increase in one variable leads to the decrease in another one, this link is called negative. Since SD has a dynamic behavior, CLD shows feedback relationships in variables to help realize the dynamics in the structure of the system (22). The reinforcing feedback loops are called positive, and the balancing loops are called negative. CLD is designed to know the behavior and interaction between complex systems (
12).
Method
In this study, the initial model of the factors affecting pharmaceutical opioids abuse was designed according to the system dynamics approach, literature, and experts’ opinions. This means that some CLD models for the relationships among the variables were proposed and evaluated.
The factors cover eight categories, including pain control, access, trust in physicians, family roles, tendency to abuse, fear of abuse, regulations, and other ones. The aim of designing factors extracted from the literature was to generate initial causal loops (
23).
After generating the initial CLD model, a mental model of experts was extracted based on their experience and knowledge (
24). To do so, ten leading experts, who are well-qualified in the treatment of chronic diseases and addiction treatment, were invited. To have a more comprehensive view, some experts practicing in Iran Drug Control Headquarters and in Iranian National Center for Addiction Studies with at least 5 years of experience also participated in this phase of study. More specifically, these experts mentioned their opinions about the factors and their relationships through an interview. This means that the interviewees were asked to add or drop variables and check the missing variables in each loop. Finally, a meeting was held in order for us to discuss the CLD model and modify the diagram. In other words, the proposed CLD model was supposed to be validated by the experts who are involved in the use of pharmaceutical opioids. Thus, model validation is an essential part of the model development to ensure that the model defines this reality properly.
The following sections discuss the structure of each loop in order to develop the final conceptual qualitative model.